Risk factors
Sarepta Therapeutics (SRPT) risk factors
Item 1A of every Sarepta Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors69 risks12 new13 dropped26 reworded
New risks center on ELEVIDYS and SRP-9004 fatal liver events, boxed warnings, and resulting adoption uncertainty.
Filed Mar 02, 2026 - FY2024 10-K risk factors70 risks
Sarepta faces heavy risks around commercial adoption, regulatory approval conditions, and third-party manufacturing dependencies for its rare disease therapies. The company relies heavily on maintaining reimbursement coverage and navigating strict post-approval requirements for products like Elevidys and its PMO portfolio.
Filed Feb 28, 2025